{
    "nct_id": "NCT05076942",
    "official_title": "Groningen International Study on Sentinel Nodes in Vulvar Cancer-III, a Prospective Phase II Treatment Trial",
    "inclusion_criteria": "* Histological confirmed primary SCC of the vulva\n* T1 tumor, not encroaching urethra/vagina/anus\n* Depth of invasion > 1mm\n* Tumor diameter < 4cm\n* Unifocal tumor\n* No enlarged (>1.5cm) or suspicious inguinofemoral lymph nodes at imaging (CT/MRI/ultrasound)\n* Possibility to obtain informed consent\n* Metastatic sentinel lymph node; size of metastasis > 2mm and / or extracapsular extension, or\n* Metastatic sentinel lymph node: more than 1 SN with metastasis ≤ 2mm\n* Patients are able to understand requirements of study, provide written informed consent and comply with the study and follow-up procedures\n* Adequate bone marrow, renal and liver function:\n\n  * Absolute neutrophil count ≥ 1.5 x 109 /L\n  * Platelet count ≥ 100 x 109 /L\n  * Creatinine clearance ≥ 40 ml/min measured by the Cockroft Gault formula\n  * Total bilirubin < 1.25 x ULN Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN\n* Performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Scale (Appendix A)\n* Age 18 years or older\n* Life expectancy of ≥ 12 weeks\n* Written informed consent\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Inoperable tumors and tumors > 4cm\n* Multifocal tumors\n* Tumors with other pathology than squamous cell carcinoma\n* Patients with enlarged / suspicious lymph nodes which are proven metastatic after fine needle aspiration cytology\n* No other carcinomas, other than basal cell carcinomas, within last 5 years\n* History of pelvic radiotherapy\n* History of any infection requiring hospitalization or antibiotics within 2 weeks before enrollment\n* Pregnant female or nursing mother\n* Desire to become pregnant\n* Known brain or spinal cord metastases unless adequately treated (surgery or radiotherapy) with no evidence of progression and neurologically stable off anticonvulsants and steroids\n* Unstable angina, myocardial infarction, cerebrovascular accident, > Class II congestive heart failure according to the New York Heart Association Classification for Congestive Heart Failure (see Appendix B) within 6 months before enrollment",
    "miscellaneous_criteria": ""
}